Ulcerative Colitis Care Pathway

Gastroenterology

Volumn 149, Issue 1, 2015, Pages 238-245

  Dassopoulos, Themistocles ^a   Cohen, Russell D ^b   Scherl, Ellen J ^c   Schwartz, Ronald M ^d   Kosinski, Lawrence ^e   Regueiro, Miguel D ^f  

^a Baylor Center for Inflammatory Bowel Diseases   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d Minnesota Gastroenterology   (United States)

^e Illinois Gastroenterology Group   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; COLON RESECTION; COLONOSCOPY; COMPARATIVE EFFECTIVENESS; DECISION MAKING; DECISION SUPPORT SYSTEM; DISEASE ACTIVITY; DRUG MONITORING; EXERCISE; HUMAN; IMMUNOGENICITY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; ULCERATIVE COLITIS; ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEALTH CARE DELIVERY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROCEDURES; TRENDS;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED;

EID: 84931326766     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.05.036     Document Type: Article

References (12)

1. W.J. Sandborn Crohn's disease evaluation and treatment: clinical decision tool Gastroenterology 147 2014 702 705
2. N. Williet, W.J. Sandborn, and L. Peyrin-Biroulet Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease Clin Gastroenterol Hepatol 12 2014 1246 1256.e6
3. P.D. Higgins, M. Schwartz, and J. Mapili Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 100 2005 355 361
4. J.D. Lewis, S. Chuai, and L. Nessel Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis Inflamm Bowel Dis 14 2008 1660 1666
5. O.J. Adedokun, W.J. Sandborn, and B.G. Feagan Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis Gastroenterology 147 2014 1296 1307.e5
6. A. Bitton, D. Buie, and R. Enns Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements Am J Gastroenterol 107 2012 179 194 author reply 195
7. A. Dignass, J.O. Lindsay, and A. Sturm Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management J Crohns Colitis 6 2012 991 1030
8. F. Carbonnel, D. Gargouri, and M. Lemann Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis Aliment Pharmacol Ther 14 2000 273 279
9. D.J. Gibson, Z.S. Heetun, and C.E. Redmond An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis Clin Gastroenterol Hepatol 13 2015 330 335
10. B.G. Feagan, J.W. McDonald, and R. Panaccione Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease Gastroenterology 146 2014 681 688.e1
11. S. Vermeire, M. Noman, and G. Van Assche Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut 56 2007 1226 1231
12. M.T. Osterman, R. Kundu, and G.R. Lichtenstein Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis Gastroenterology 130 2006 1047 1053